OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer

被引：0
|
作者：
Nicum, S. [1 ]
Strauss, V. Y. [2 ]
McGregor, N. [3 ]
McNeish, I. [4 ]
Roux, R. [1 ]
Hall, M. [5 ]
Michael, A. [6 ]
Roberts, C. [2 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England
[2] Univ Oxford, Ctr Stat Med, Oxford, England
[3] Univ Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England
[4] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland
[5] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Stevenage, Middx, England
[6] Univ Surrey, Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
989TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] MAINTENANCE TREATMENT WITH OLAPARIB IN BRCA-MUTATED HIGH GRADE SEROUS OVARIAN CANCER (HGSOC): OUR EXPERIENCE IN A CASE REPORT
    Mainella, A.
    Giacomi, N.
    Marmissolle, F.
    Vigo, S.
    Price, P.
    Sansano, M.
    Lujan, M. L.
    Zapata Caamano, G.
    Dominguez, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1585 - 1585
  • [32] BUDGET IMPACT ANALYSIS FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN COSTA RICA
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    Landaverde, D.
    Gonzalez, I
    VALUE IN HEALTH, 2018, 21 : S21 - S21
  • [33] Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer
    Kim, Ji Hyun
    Kim, Se Ik
    Park, Eun Young
    Kim, Eun Taeg
    Kim, Hyesu
    Kim, Sangeon
    Park, Sang-Yoon
    Lim, Myong Cheol
    GYNECOLOGIC ONCOLOGY, 2024, 181 : 33 - 39
  • [34] Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study
    Bourien, Heloise
    Lefevre, Leila Bengrine
    Mouret-Reynier, Marie-Ange
    Asselain, Bernard
    Lucas, Brigitte
    Gavoille, Celine
    Cornila, Corina
    Gavoille, Laurene
    Colomba, Emeline
    Patsouris, Anne
    Fabbro, Michel
    Chakiba, Camille
    Toussaint, Philippe
    Simon, Helene
    Berton, Dominique
    Garbay, Delphine
    Tixidre, Claire Garnier
    Coeffic, David
    Morvan, Aurelie
    Collard, Olivier
    Rouge, Thibault De La Motte
    ANTICANCER RESEARCH, 2023, 43 (02) : 653 - 662
  • [35] PARTNER randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, Jean
    Vallier, Anne-Laure
    Qian, Wendi
    Grybowicz, Louise
    Thomas, Stanly
    Machin, Andrea
    Harvey, Caron
    Chiu, Edmund
    McAdam, Karen
    Hughes-Davies, Luke
    Roylance, Rebecca
    Copson, Ellen
    Armstrong, Anne
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    CANCER RESEARCH, 2018, 78 (04)
  • [36] Phase II study of olaparib plus durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    Kaufman, B.
    Banerjee, S.
    Lortholary, A.
    Hong, S. H.
    Park, Y. H.
    Zimmermann, S.
    Roxburgh, P.
    Ferguson, M.
    Alvarez, R. H.
    Domchek, S.
    Gresty, C.
    Angell, H. K.
    Ros, V. Rocher
    Meyer, K.
    Lanasa, M.
    Herbolsheimer, P.
    de Jonge, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Oza, Amit M.
    Cibula, David
    Oaknin Benzaquen, Ana
    Poole, Christopher
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Holger
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Lowe, Elizabeth S.
    Dougherty, Brian
    Barrett, J. Carl
    Friedlander, Michael
    LANCET ONCOLOGY, 2015, 16 (01): : 87 - 97
  • [38] Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
    Lee, J-M.
    Miller, A.
    Rose, P.
    AlHilli, M.
    Washington, C.
    John, V.
    Shah, C.
    Matsuo, K.
    Siedel, J.
    Miller, D. S.
    Chan, J.
    Hopp, E.
    Kohn, E. C.
    Moore, K. N.
    Liu, J. F.
    ANNALS OF ONCOLOGY, 2023, 34 : S511 - S511
  • [39] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
    Fanucci, Kristina A.
    Pilat, Mary Jo
    Shyr, Derek
    Shyr, Yu
    Boerner, Scott A.
    Durecki, Diane
    Noonan, Anne
    Abramson, Vandana
    Santa-Maria, Cesar
    Han, Hyo
    Nanda, Rita
    Dees, Elizabeth Claire
    Park, Haeseong
    Buys, Saundra
    Peswani, Namrata
    Chew, Helen
    Assad, Hadeel
    Wulf, Gerburg
    Richardson, Angelique
    Trivedi, Meghna S.
    Brufsky, Adam
    Abbruzzese, James
    Afghahi, Anosheh
    Sharon, Elad
    Schalper, Kurt
    LoRusso, Patricia
    CANCER RESEARCH, 2023, 83 (08)
  • [40] Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study
    Ales-Martinez, Jose E.
    Balmana, Judith
    Sanchez-Rovira, Pedro
    Bofill, Francisco Javier Salvador
    Garcia-Saenz, Jose Angel
    Pimentel, Isabel
    Murillo, Serafin Morales
    Fernandez, Adela
    Martinez, Ainhara Lahuerta
    Ferrer, Neus
    Zamora, Pilar
    Bermejo, Begona
    Diaz-Redondo, Tamara
    Lopez-Ceballos, Maria Helena
    Galan, Maria
    Malfettone, Andrea
    Calabuig, Laura
    Sampayo-Cordero, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2023, 83 (05)
12345